Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 19/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30493567 | 1.00 | PARP1 (0.54) | PARP1PARP2 | |
| SCHEMBL29907155 | 0.89 | PARP1 (0.53) | PARP1PARP2 | |
| SCHEMBL29907150 | 0.89 | PARP1 (0.53) | PARP1PARP2 | |
| SCHEMBL25093040 | 0.86 | PARP1 (0.54) | PARP1 | |
| SCHEMBL24649793 | 0.86 | PARP1 (0.54) | PARP1 | |
| SCHEMBL26451092 | 0.86 | PARP1 (0.57) | PARP1PARP2 | |
| SCHEMBL29907151 | 0.84 | PARP1 (0.53) | PARP1 | |
| SCHEMBL25791405 | 0.83 | PARP1 (0.54) | PARP1PARP2 | |
| SCHEMBL25605323 | 0.82 | PARP1 (0.67) | PARP1PARP2 | |
| SCHEMBL24649820 | 0.81 | PARP1 (0.47) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289800-A1 | Selective Parp1 Inhibitor And Application Thereof | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| US-20250221987-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2025-07-10 | — | — | US | disclosed |
| WO-2025011494-A1 | CRYSTAL FORM OF PIPERAZINO RING-CONTAINING DERIVATIVE, SALT FORM, PREPARATION METHOD, AND USE | 优领医药科技(香港)有限公司 | 2025-01-16 | — | — | WO | disclosed |
| EP-4464704-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Acerand Therapeutics (Hong Kong) Limited (HK) | 2024-11-20 | — | — | EP | disclosed |
| EP-4434985-A1 | SELECTIVE PARP1 INHIBITOR AND APPLICATION THEREOF | Kangbaida (Sichuan) Biotechnology Co., Ltd. (CN) | 2024-09-25 | — | — | EP | disclosed |
| CN-118055933-A | Selective PARP1 inhibitors and uses thereof | 成都百裕制药股份有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-116867784-A | Pyridine derivative and application thereof in medicine | 成都百裕制药股份有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-116710433-A | Selective PARP1 inhibitor and application thereof | 成都百裕制药股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023134647-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 优领医药科技(香港)有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023134647-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 优领医药科技(香港)有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023088408-A1 | SELECTIVE PARP1 INHIBITOR AND APPLICATION THEREOF | 成都百裕制药股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2023088408-A1 | SELECTIVE PARP1 INHIBITOR AND APPLICATION THEREOF | 成都百裕制药股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2022222965-A1 | PYRIDINE DERIVATIVE AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2022-10-27 | — | — | WO | disclosed |
| WO-2022222966-A1 | SELECTIVE PARP1 INHIBITOR AND APPLICATION THEREOF | 成都百裕制药股份有限公司 | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221987-A1 | PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | PARP1, PARP11, PARP15 | PARP1 1/4885PARP2 6/4885 |
| US-20250289800-A1 | Selective Parp1 Inhibitor And Application Thereof | PARP1, PARP11, PARP12 | PARP1 1/4885PARP2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.